Effect of Paricalcitol Over Vessel Wall

Phase 4TerminatedNCT02372695

Effice Servicios Para la Investigacion S.L.50 enrolled

Overview

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nephropathy

Interventions

ParicalcitolDRUG

Eligibility

Sex: ALLMin age: 50 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged between 50 and 75 years. * Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD). * Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml. * Plasma concentrations of 25 (OH) vitamin D \<30 ng/ml. * Without vitamin D supplementation for 3 months before the study. * Serum P\> 3.8 mg / dl. * Serum Ca\> 9.8 mg / dl. * No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease). * No exclusion criteria for the use of contrast. Exclusion Criteria: * Allergic reaction to sulfur hexafluoride. * Recent unstable cardiac symptoms. * Patients with recent coronary intervention (\<7 days) * Patients with class III and IV heart failure or severe arrhythmias. * Severe pulmonary hypertension.

Outcomes

Primary Outcomes

Prevention on vessels progression based on paricalcitol intake.

Time frame: participants will be followed for the duration of whole study, an expected average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.